Multiple studies have indicated that FOXC1 upregulation is related to poor prognosis in many cancer types, including acute myeloid leukemia [8], basal-like breast cancer [9], liver cancer [10], pancreatic ductal adenocarcinoma [11], and gastric cancer [12]. Here, FOXC1 is linked to pancreatic ductal adenocarcinoma.